Immunotherapy

All articles by Immunotherapy

Mural Oncology spins out from Alkermes with $275M, lead immunotherapy program
Mural Oncology spins out from Alkermes with $275M, lead immunotherapy program
Marc Iskowitz
November 16, 2023
11:58 am

The spinoff between Mural and Alkermes created two pure-play companies.

Roivant’s Covant Therapeutics and BI join forces to explore covalent drug space
Roivant’s Covant Therapeutics and BI join forces to explore covalent drug space
Marc Iskowitz
March 28, 2023
2:50 pm

As part of the co-development deal with BI, Covant gets $10 million upfront and up to $471 million in potential milestones and tiered royalties.

Jounce renounces Redx Pharma deal, agrees to be acquired by Concentra
Jounce renounces Redx Pharma deal, agrees to be acquired by Concentra
Larry Dobrow
March 27, 2023
12:01 pm

The deal comes after Jounce’s board withdrew its recommendation to pursue a merger with Redx.

Elicio Therapeutics merges with Angion Biomedica to focus on cancer vaccines and immunotherapies
Elicio Therapeutics merges with Angion Biomedica to focus on cancer vaccines and immunotherapies
Lecia Bushak
January 17, 2023
10:57 am

The combined company will continue under the Elicio Therapeutics name and focus on its lead candidate, ELI-002.

Gilead buys remaining rights to Jounce’s immunotherapy GS-1811
Gilead buys remaining rights to Jounce’s immunotherapy GS-1811
Jack O'Brien
December 28, 2022
11:23 am

Jounce will not be eligible for the remaining contingent payments of up to $645 million in milestones or royalties based upon worldwide sales under the original license agreement.

Gilead snaps up Dragonfly’s NK program, has options for more
Gilead snaps up Dragonfly’s NK program, has options for more
Jack O'Brien
May 2, 2022
10:00 am

The $300 million Dragonfly deal seeks to expand Gilead’s oncology portfolio, which saw sales surge 60% last quarter to $420 million.

Five things for pharma marketers to know: Friday, December 8, 2017
Five things for pharma marketers to know: Friday, December 8, 2017
Virginia Lau
December 8, 2017
3:20 pm

FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance

Five things for pharma marketers to know: Thursday, July 6, 2017
Five things for pharma marketers to know: Thursday, July 6, 2017
Virginia Lau
July 6, 2017
2:20 pm

The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial

Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs
Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs
Kevin McCaffrey
June 4, 2017
4:16 pm

Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.

Five things for pharma marketers to know: Thursday, May 11, 2017
Five things for pharma marketers to know: Thursday, May 11, 2017
Virginia Lau
May 11, 2017
2:40 pm

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

  • From Our Partners